Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
therapeutics tags : Potential save search
Compugen Publishes Paper in Cancer Immunology Research Demonstrating Therapeutic Potential of COM503
Published: 2024-04-10 (Crawled : 13:00) - biospace.com/
CGEN | $2.03 3.57% 3.45% 450K
|
Health Technology
|
| O: -2.97%
H: 0.0%
C: 0.0%
com503 cancer research immunology potential
Foghorn Therapeutics Presents New Preclinical Data on Potential First-in-Class BRM Selective Inhibitor FHD-909 and Selective CBP and Selective EP300 Degrader Oncology Programs
Published: 2024-04-09 (Crawled : 21:00) - globenewswire.com
FHTX | $5.58 -3.46% -3.58% 130K
|
Health Technology
|
| O: -4.01%
H: 9.92%
C: 1.11%
fhd-909 ep300 preclinical therapeutics potential
Tenax Therapeutics to Host KOL Event: “LEVEL Setting: the Scientific Rationale for Levosimendan as a Potential First Treatment for PH-HFpEF, and the Ongoing Phase 3 LEVEL Study”
Published: 2024-04-09 (Crawled : 12:30) - globenewswire.com
TENX | $3.67 2.23% 2.18% 21K
|
Health Technology
|
| O: 7.89%
H: 1.95%
C: -2.93%
first levosimendan treatment ongoing for therapeutics potential
Omega Therapeutics Presents New Preclinical Data at AACR 2024 Supporting the Potential of Precision Epigenomic Control
Published: 2024-04-09 (Crawled : 11:00) - globenewswire.com
OMGA | $2.42 -5.28% -5.58% 360K
|
|
| O: 4.65%
H: 0.32%
C: -4.13%
precision control preclinical therapeutics potential
GenFleet Therapeutics Announces Potent Anti-tumor Efficacy of GFH375, an Oral KRAS G12D (ON/OFF) Inhibitor, and its Potential in Combination Therapy with RAF/MEK Clamp at 2024 AACR Annual Meeting
Published: 2024-04-09 (Crawled : 11:00) - prnewswire.com
VSTM | $10.19 -6.0% -6.38% 67K
|
Health Technology
|
| O: 5.64%
H: 1.41%
C: -2.89%
gfh375 meeting therapeutics potential therapy
Poseida Therapeutics Presents New Phase 1 Data at AACR 2024 Supporting Potential of P-BCMA-ALLO1 Allogeneic CAR-T Therapy to Benefit Broad Range of Patients with Multiple Myeloma
Published: 2024-04-08 (Crawled : 00:00) - biospace.com/
PSTX | News | $2.005 -1.72% -1.75% 520K
|
Health Technology
|
| O: -0.67%
H: 0.0%
C: 0.0%
car-t therapeutics potential therapy
ZyVersa Therapeutics Highlights Published Data Demonstrating NLRP3 Inflammasome Inhibition Has Potential to Decrease Atherosclerotic Lesions in Patients with Diabetes
Published: 2024-04-04 (Crawled : 12:00) - globenewswire.com
ZVSA | $0.6265 7.55% 7.02% 430K
|
|
| O: 7.38%
H: 2.6%
C: -3.23%
therapeutics diabetes potential
Global Ginger Market Analysis Report 2023-2030: Versatility Expands Across Industries, Exploring Therapeutic Applications, Potential in Skincare and Pharmaceuticals
Published: 2024-03-27 (Crawled : 09:00) - prnewswire.com
MEDE | News | $0.51 0% 500
|
n/a
| Email alert
Add to watchlist
report pharmaceuticals global potential market
Foghorn to Host Conference Call and Webcast on Pipeline of Potential First-in-Class Medicines in Conjunction with the 2024 AACR Annual Meeting
Published: 2024-03-26 (Crawled : 11:00) - globenewswire.com
FHTX | $5.58 -3.46% -3.58% 130K
|
Health Technology
|
| O: 2.19%
H: 2.39%
C: 0.0%
conference pipeline meeting potential
Stoke Therapeutics Announces Landmark New Data That Support the Potential for STK-001 to be the First Disease-Modifying Medicine for the Treatment of Patients with Dravet Syndrome
Published: 2024-03-25 (Crawled : 23:00) - biospace.com/
STOK | $11.66 -0.51% -0.51% 1.1M
|
Health Technology
|
| O: -0.16%
H: 8.11%
C: 3.34%
stk-001 first treatment therapeutics potential
Athira Pharma Presents Clinical and Preclinical Data Supporting Therapeutic Potential of Fosgonimeton in Alzheimer’s and Parkinson’s Diseases at AD/PD™ 2024 International Conference
Published: 2024-03-08 (Crawled : 12:00) - globenewswire.com
ATHA | $2.07 -1.9% -1.93% 200K
|
Health Technology
|
| O: 0.0%
H: 1.45%
C: -13.73%
fosgonimeton pharma conference alzheimer’s international preclinical parkinson’s potential
Foghorn Therapeutics to Present New Preclinical Data at 2024 AACR Annual Meeting, Reflecting Advances with Multiple Potential First-in-Class Medicines, including the Selective Inhibitor of BRM, FHD-909
Published: 2024-03-05 (Crawled : 22:00) - globenewswire.com
FHTX | $5.58 -3.46% -3.58% 130K
|
Health Technology
|
| O: 0.0%
H: 11.74%
C: 6.26%
fhd-909 preclinical therapeutics potential
ZyVersa Therapeutics Publishes New White Paper Detailing the Role of Inflammasomes and ASC Specks in Neurological Diseases, and Data Supporting Inflammasome ASC Inhibitor IC 100 as a Potential Therapeutic Option
Published: 2024-02-22 (Crawled : 13:00) - globenewswire.com
ZVSA | $0.6265 7.55% 7.02% 430K
|
|
| O: 1.64%
H: 17.44%
C: 0.05%
neurological therapeutics 100 potential
Aileron Therapeutics and Pulmonary Care Experts To Discuss the Potential Implications of LTI-03 for Idiopathic Pulmonary Fibrosis in Virtual Key Opinion Leader Event
Published: 2024-02-15 (Crawled : 21:00) - globenewswire.com
ALRN | $5.01 17.88% 15.17% 1.8M
|
Health Technology
|
| O: -4.27%
H: 4.69%
C: 4.69%
lti-03 care fibrosis key therapeutics potential
Protagenic Therapeutics Achieves First Clinical Safety Milestone with its Novel Neuropeptide for the Potential Treatment of Stress-Related Disorders
Published: 2024-02-13 (Crawled : 14:30) - biospace.com/
PTIX 4 | $1.43 5.93% 5.59% 5.8K
|
Administrative and Support and ...
|
| O: 4.25%
H: 20.0%
C: -3.0%
first disorders treatment therapeutics potential milestone
Sangamo Therapeutics Announces U.S. FDA Alignment on Abbreviated Pathway to Potential Approval and EMA Prime Eligibility for ST-920 in Fabry Disease
Published: 2024-02-12 (Crawled : 14:30) - biospace.com/
SGMO | $0.4853 -5.95% -6.33% 1.7M
|
Health Technology
|
| O: 8.46%
H: 35.96%
C: 29.21%
st-920 fda disease approval prime ema therapeutics potential
Athira Pharma Announces Publication in Frontiers in Neuroscience Highlighting Therapeutic Potential of ATH-1105 in Amyotrophic Lateral Sclerosis (ALS)
Published: 2024-02-08 (Crawled : 21:00) - globenewswire.com
ATHA | $2.07 -1.9% -1.93% 200K
|
Health Technology
|
| O: 1.89%
H: 3.72%
C: 2.79%
ath-1105 pharma publication sclerosis potential
New Publication in Nature Medicine Supports Therapeutic Potential of Senolytics to Provide Long-lasting, Disease-modifying Intervention in Vision Loss
Published: 2024-02-06 (Crawled : 13:00) - globenewswire.com
UBX | $1.5 -0.33% -0.33% 28K
|
Health Technology
|
| O: 0.0%
H: 3.57%
C: 2.98%
publication potential
Chemomab Therapeutics Announces New Publication Reinforcing the Clinical Potential of Its CCL24-Neutralizing Antibody CM-101 in Primary Sclerosing Cholangitis
Published: 2024-01-30 (Crawled : 13:00) - biospace.com/
CMMB | News | $0.629 6.61% 6.2% 30K
|
Manufacturing
|
| O: 5.56%
H: 5.26%
C: 1.75%
ccl24 antibody publication cm-101 therapeutics potential
ZyVersa Therapeutics Announces Peer-Reviewed Article Supporting the Therapeutic Potential of Targeting ASC Specks During Progression of Alzheimer’s Disease
Published: 2024-01-24 (Crawled : 13:00) - globenewswire.com
ZVSA | $0.6265 7.55% 7.02% 430K
|
|
| O: 4.07%
H: 1.56%
C: 1.55%
disease alzheimer’s therapeutics potential
Gainers vs Losers
| 64% | 36% |
Top 10 Gainers
AGBA | News | $1.02 155.0% 57.94% 120M
|
Finance
ZCMD | $2.86 108.76% 52.1% 2.3M
|
Commercial Services
INVO | $1.555 104.6% 51.13% 5M
|
Health Technology
ISPC | $0.437 105.16% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | News | $0.92 84.0% 45.65% 1.6M
|
OST | $0.499 21.38% 45.26% 1.9M
|
XPON | News | $3.1 60.62% 37.74% 17M
|
TIRX | $0.7 44.39% 30.74% 58M
|
BNTC | News | $6.92 44.17% 30.64% 3.5M
|
Health Technology
GGE | $0.035 19.86% 29.3% 64M
|
Your saved searches
Save your searches and get alerts when important news are released.